DK0592546T3 - Immundeficiens-virus rekombinant poxvirus-vaccine - Google Patents

Immundeficiens-virus rekombinant poxvirus-vaccine

Info

Publication number
DK0592546T3
DK0592546T3 DK92914713T DK92914713T DK0592546T3 DK 0592546 T3 DK0592546 T3 DK 0592546T3 DK 92914713 T DK92914713 T DK 92914713T DK 92914713 T DK92914713 T DK 92914713T DK 0592546 T3 DK0592546 T3 DK 0592546T3
Authority
DK
Denmark
Prior art keywords
immunodeficiency virus
virus
recombinant poxvirus
virus recombinant
poxvirus vaccine
Prior art date
Application number
DK92914713T
Other languages
Danish (da)
English (en)
Inventor
Enzo Paoletti
James Tartaglia
William I Cox
Robert Gallo
Genoveffa Franchini
Original Assignee
Us Gov Health & Human Serv
Connaught Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Connaught Technology Corp filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of DK0592546T3 publication Critical patent/DK0592546T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK92914713T 1991-06-14 1992-06-12 Immundeficiens-virus rekombinant poxvirus-vaccine DK0592546T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71592191A 1991-06-14 1991-06-14
US89738292A 1992-06-11 1992-06-11
PCT/US1992/005107 WO1992022641A1 (fr) 1991-06-14 1992-06-12 Vaccin a base de poxvirus recombine comprenant le virus de l'immunodeficience

Publications (1)

Publication Number Publication Date
DK0592546T3 true DK0592546T3 (da) 2003-09-15

Family

ID=27109438

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92914713T DK0592546T3 (da) 1991-06-14 1992-06-12 Immundeficiens-virus rekombinant poxvirus-vaccine

Country Status (8)

Country Link
EP (2) EP1156102A1 (fr)
JP (1) JP3504659B2 (fr)
AT (1) ATE241696T1 (fr)
AU (3) AU672581B2 (fr)
CA (1) CA2110489A1 (fr)
DE (1) DE69233080T2 (fr)
DK (1) DK0592546T3 (fr)
WO (1) WO1992022641A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5856088A (en) * 1989-07-11 1999-01-05 Gen-Probe Incorporated Detection of human immunodeficiency virus type 1
US6589734B1 (en) 1989-07-11 2003-07-08 Gen-Probe Incorporated Detection of HIV
WO1992015672A1 (fr) * 1991-03-07 1992-09-17 Virogenetics Corporation Souche de vaccin mise au point par genie genetique
US5766597A (en) * 1991-03-07 1998-06-16 Virogenetics Corporation Malaria recombinant poxviruses
US5863542A (en) * 1991-03-07 1999-01-26 Virogenetics Corporation Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts
AU702634B2 (en) * 1991-03-07 1999-02-25 Virogenetics Corporation Immunodeficiency recombinant poxvirus
WO1992016616A1 (fr) * 1991-03-20 1992-10-01 Virogenetics Corporation Vaccin contre le poxvirus de recombinaison de la malaria
EP1156102A1 (fr) * 1991-06-14 2001-11-21 Virogenetics Corporation Vaccin à base de poxvirus recombinant comprenant le virus de l'immunodéficience
JP3706130B2 (ja) * 1992-01-13 2005-10-12 ヴァイロジェネティクス コーポレイション マレック病ウイルス組換えポックスウイルスワクチン
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
US6136318A (en) * 1993-02-26 2000-10-24 Cochran; Mark D. Recombinant fowlpox viruses and uses thereof
AU696247B2 (en) * 1993-02-26 1998-09-03 Syntro Corporation Recombinant fowlpox viruses and uses thereof
US5925358A (en) * 1993-02-26 1999-07-20 Syntro Corporation Recombinant fowlpox viruses and uses thereof
JP4108118B2 (ja) 1993-03-26 2008-06-25 ジェン−プローブ・インコーポレイテッド ヒト・免疫不全ウイルス１型の検出
JPH08511007A (ja) * 1993-06-09 1996-11-19 コノート ラボラトリーズ リミテッド タンデム合成ｈｉｖ−１ペプチド
FR2720077B1 (fr) * 1994-05-18 1996-08-09 Univ Rennes Procédé d'amplification enzymatique in vitro d'un fragment d'ADN à l'aide d'amorces en escalier.
US5656427A (en) * 1994-08-29 1997-08-12 Gen-Probe Incorporated Nucleic acid hybridization assay probes, helper probes and amplification oligonucleotides targeted to Mycoplasma pneumoniae nucleic acid
US6723558B1 (en) 1996-01-23 2004-04-20 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
WO1998000166A1 (fr) 1996-07-03 1998-01-08 Merial, Inc. ADENOVIRUS CANIN DE RECOMBINAISON (ACR) CONTENANT DE l'ADN EXOGENE
US5990091A (en) * 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
US6224882B1 (en) 1997-11-07 2001-05-01 Protein Science Corp. Insect cells or fractions as adjuvant for antigens
AUPP700798A0 (en) * 1998-11-09 1998-12-03 Australian National University, The Recombinant viral constructs and methods relating thereto
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
EP1450854A2 (fr) 2001-11-30 2004-09-01 Isis Innovation Limited Vaccin
ITFI20050098A1 (it) * 2005-05-10 2006-11-11 Domenico Acanfora Composizione farmaceutica per il trattamento della immunodeficienza acquisita
GB2460694A (en) * 2008-06-06 2009-12-09 Secr Defence Attenuated poxviruses
WO2012023033A2 (fr) 2010-08-18 2012-02-23 Purdue Pharma L.P. Immunogènes peptidiques améliorés
AP2013007166A0 (en) 2011-04-06 2013-10-31 Univ Paris Descartes Inst De Rech Pour Le Dev Ird Pharmaceutical compositions for preventing and/or treating an HIV disease in humans
EP2788021B1 (fr) 2011-12-09 2017-01-18 Bavarian Nordic A/S Vecteur du poxvirus codant des antigènes bactériens lié à le fragment c de la toxine tétanique
US9463238B2 (en) 2011-12-09 2016-10-11 Bavarian Nordic A/S Recombinant poxvirus vector comprising tetanus toxin fragment C

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10399032I1 (de) * 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
AU3775789A (en) * 1988-06-10 1990-01-05 Applied Biotechnology, Inc. A method of evaluating recombinant vaccines against immunodeficiency virus
WO1990010693A1 (fr) * 1989-03-08 1990-09-20 Health Research, Inc. Systeme de selection d'hotes de poxvirus de recombinaison
GB8907468D0 (en) * 1989-04-03 1989-05-17 Smith Geoffrey L Vaccinia vectors,vaccinia genes and expression products thereof
IE71643B1 (en) * 1990-11-20 1997-02-26 Virogenetics Corp A recombinant poxviral vaccine for canine distemper
WO1992011028A1 (fr) * 1990-12-19 1992-07-09 Epitope, Inc. Vaccin a transcriptase inverse contre le vih
WO1992015672A1 (fr) * 1991-03-07 1992-09-17 Virogenetics Corporation Souche de vaccin mise au point par genie genetique
EP1156102A1 (fr) * 1991-06-14 2001-11-21 Virogenetics Corporation Vaccin à base de poxvirus recombinant comprenant le virus de l'immunodéficience

Also Published As

Publication number Publication date
AU6564696A (en) 1997-02-13
EP0592546B1 (fr) 2003-05-28
AU716480B2 (en) 2000-02-24
DE69233080D1 (de) 2003-07-03
AU712431B2 (en) 1999-11-04
EP1156102A1 (fr) 2001-11-21
JPH06508037A (ja) 1994-09-14
ATE241696T1 (de) 2003-06-15
JP3504659B2 (ja) 2004-03-08
DE69233080T2 (de) 2004-04-15
AU6564596A (en) 1997-02-13
AU2259792A (en) 1993-01-12
EP0592546A4 (fr) 1994-10-12
EP0592546A1 (fr) 1994-04-20
WO1992022641A1 (fr) 1992-12-23
CA2110489A1 (fr) 1992-12-23
AU672581B2 (en) 1996-10-10

Similar Documents

Publication Publication Date Title
DK0592546T3 (da) Immundeficiens-virus rekombinant poxvirus-vaccine
GB2269820A (en) Flavivirus recombinant poxvirus vaccine
CA2014465A1 (fr) Vaccin de poxvirus contenant de l'adn du virus de l'herpes
DK0835133T3 (da) Rekombinant koppevirus-rabies-præparater og kombinationspræparater samt anvendelser deraf
PL352201A1 (en) Porcine circovirus vaccine in recombinant poxvirus
EE9900343A (et) Sünteetiline polünukleotiid, immuunvastuste tekitamise meetod, immunogeenne kompositsioon, anti-HIV immuunvastuste indutseerimise meetod, meetod antigeeni tekitava raku indutseerimiseks ja farmatseutiline kompositsioon
AR003425A1 (es) Poxvirus recombinante de mapache, vacuna para uso en gatos y uso de poxvirus para preparar una vacuna util para evitar o para disminuir la enfermedad causada por el virus de inmunodeficiencia felina (fiv)
PT83434B (pt) Processo de preparacao de virus recombinantes, de peptidos ou proteinas e de vacinas contra o sindroma de imunodeficiencia adquirida
DK0437604T3 (da) Rekombinant poxvirus- og streptokok M-proteinvaccine
DE69130071T2 (de) Zusammensetzung verwendbar als therapeutisches mittel gegen chronische virale leberkrankheiten
FR2620459B1 (fr) Virus recombinant de la vaccine
ATE359089T1 (de) Peptide zum induzieren einer antwort der zytotoxischen t-lymphozyten gerichtet gegen das hepatitis-b-virus
ITMI913092A1 (it) Vaccino di poxvirus ricombinante del virus del morbillo
EP0289550A4 (fr) Vaccin utilise pour le traitement therapeutique de hsv.
PT868522E (pt) Virus recombinante de poxvirus - virus da peritonite infecciosa felina, suas composicoes e metodos para a sua preparacao e utilizacao
BR9403202A (pt) Método de produção de anticorpos ou imunidade mediada por célula a vírus de imunodeficiência humana, método de proteção contra infecção de vírus de imunodeficiência humana, vacina e adenovírus recombinante
PT623172E (pt) Vacina de virus vaccinia recombinante do virus da doenca de marek
RU96116005A (ru) Штамм hominis immunodeficiti virus (hiv-i) вич-i/россия/гм-12-95 (ru1295) субтипа в для диагностических и вакцинных препаратов
RU94010320A (ru) Живая рекомбинантная вакцина гепатита в на основе вируса осповакцины для перорального применения и способ ее получения